The BRAF mutations in skin and colorectal cancer likewise sensitize to different BRAF inhibitors in both the GDSC and PRISM drug data, and also to BRAF gene disruption (Fig. 3b and Supplementary Fig. 9d). The gene discussed is BRAF; the disease is colorectal cancer.